25 results
DEFM14A
CYT
Cyteir Therapeutics Inc
12 Oct 23
Proxy related to merger
4:14pm
. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses
8-K
EX-10.1
CYT
Cyteir Therapeutics Inc
5 Oct 23
Entry into a Material Definitive Agreement
4:00pm
no rights to any credit, claim, cause of action, offset or similar charge against Landlord or the Base Rent existing as of the date hereof, and (iii
PREM14A
CYT
Cyteir Therapeutics Inc
2 Oct 23
Preliminary proxy related to merger
4:44pm
of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the Non-U.S. Holder
8-K
EX-99.1
gb7 f5jpwh50
10 May 23
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
4:02pm
S-3
ku7bg8dw53h4
8 Aug 22
Shelf registration
5:29pm
8-K
EX-99.1
0b04fqi 1oxt
8 Aug 22
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
4:07pm
10-K
jkzhcatqksc9uw0kogn
16 Mar 22
Annual report
4:08pm
10-Q
ke4ssa2xpyhce4jm80b
9 Aug 21
Quarterly report
4:28pm
8-K
EX-99.1
u7n88ra3
2 Jul 21
Entry into a Material Definitive Agreement
4:05pm
424B4
u47yi1q wosg5qn3lnq
21 Jun 21
Prospectus supplement with pricing info
6:13am
S-1/A
agotl5o3ud86ji7h7
4 Jun 21
IPO registration (amended)
4:32pm
S-1
EX-10.1
u2op0edpgt hlvsuaoj
28 May 21
IPO registration
4:01pm